Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy

NCT00329043

Last updated date
Study Location
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Prostate Cancer
Sex
Male
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0 +
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Patients with histologically confirmed adenocarcinoma of the prostate that in the opinion of the surgeon is resectable. Ductal adenocarcinoma of the prostate is included.

2. All patients must be regarded as low anesthetic risk for radical prostatectomy and confirm their intention to undergo radical prostatectomy at the end of the neoadjuvant therapy.

3. All patients must have one of the following high-risk features: clinical (c) T(subscript)3 disease or Gleason 8-10 adenocarcinoma or cT(subscript)2(subscript)b-c and PSA >= 10 ng/ml and Gleason 7 adenocarcinoma. The 1992 AJCC staging system will be followed.

4. ECOG performance status 0 or 1.

5. Prior hormonal therapy up to 2 months is permitted.

6. Patients must have adequate bone marrow function defined as an absolute peripheral granulocyte count of >= 1,500/mm^3 and platelet count of >= 100,000/mm^3; hemoglobin >= 9.0g/dl; adequate hepatic function defined as a total bilirubin of <=1.5 mg/dl and AST/ALT <= 2 x the upper limit of normal; adequate renal function defined as serum creatinine <= 1.5 x the upper limits of normal or creatinine clearance >= 40cc/min (measured or calculated).

7. Patients must sign the current IRB approved informed consent indicating that they are aware of the investigational nature of this study, in keeping with the policies of the institution.

8. All patients must have a surgical and medical oncology consult prior to signing informed consent.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


1. Patients with small cell or sarcomatoid prostate cancers are not eligible.


2. Patients with clinical or radiological evidence of metastatic disease.


3. Patients receiving ketoconazole as a prior hormonal therapy.


4. Prior chemotherapy or experimental agents for prostate cancer.


5. Patients with any infection process, in the criterion of the investigator, that could
worsen or its outcome be affected, as a result of the investigational therapy.


6. Patients with NYHA Class III/IV congestive heart failure, unstable angina,
cerebrovascular accident or transient ischemic attack, or pulmonary embolism or
myocardial infarction in the last 6 months.


7. Uncontrolled severe hypertension (>= 140/90 despite controlling medication),
uncontrolled diabetes mellitus, oxygen-dependent lung disease, known chronic liver
disease or HIV infection.


8. Second malignancies (excluding non-melanoma skin cancer) unless disease-free for 3
years.


9. Ongoing treatment with therapeutic doses of coumadin. However, low dose coumadin up to
2mg PO daily for deep vein thrombosis prophylaxis is allowed. Low molecular weight
heparin is allowed.


10. Overt psychosis, mental disability or otherwise incompetent to give informed consent
or history of non-compliance.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Prostate CancerA Study of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Prostate Cancer
NCT00218205
  1. East Orange, New Jersey
Male
18 Years+
years
MULTIPLE SITES
Prostate CancerMultimodality Phase II Study in Prostate Cancer
NCT00734851
  1. Baltimore, Maryland
  2. New Brunswick, New Jersey
  3. Durham, North Carolina
Male
18 Years+
years
MULTIPLE SITES
Prostate CancerStudy on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer
NCT02918968
  1. Nagoya, Aichi
  2. Nagoya, Aichi
  3. Matsuyama, Ehime
  4. Iizuka, Fukuoka
  5. Isesaki, Gunma
  6. Maebashi, Gunma
  7. Ota, Gunma
  8. Hakodate, Hokkaido
  9. Sapporo, Hokkaido
  10. Sapporo, Hokkaido
  11. Sapporo, Hokkaido
  12. Mito, Ibaraki
  13. Sagamihara, Kanagawa
  14. Yokohama, Kanagawa
  15. Yokohama, Kanagawa
  16. Yokosuka, Kanagawa
  17. Kashihara, Nara
  18. Kurashiki, Okayama
  19. Hirakata, Osaka
  20. Osakasayama, Osaka
  21. Suita, Osaka
  22. Kitaadachi-gun, Saitama
  23. Hamamatsu, Shizuoka
  24. Utsunomiya, Tochigi
  25. Bunkyo-ku, Tokyo
  26. Bunkyo-ku, Tokyo
  27. Koto-ku, Tokyo
  28. Nakano-ku, Tokyo
  29. Shinagawa-ku, Tokyo
  30. Shinjuku-ku, Tokyo
  31. Ube, Yamaguchi
  32. Chiba,
  33. Chiba,
  34. Fukuoka,
  35. Fukuoka,
  36. Fukuoka,
  37. Hiroshima,
  38. Kyoto,
  39. Nagano,
  40. Nagano,
  41. Nagasaki,
  42. Osaka,
  43. Osaka,
  44. Osaka,
  45. Saga,
  46. Tokushima,
  47. Toyama,
Male
20 Years+
years
MULTIPLE SITES
Prostate CancerPalbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT02905318
  1. Edmonton, Alberta
  2. Vancouver, British Columbia
  3. Halifax, Nova Scotia
  4. Hamilton, Ontario
  5. London, Ontario
  6. Ottawa, Ontario
  7. Toronto, Ontario
  8. Montreal, Quebec
  9. Montreal, Quebec
  10. Regina, Saskatchewan
  11. Saskatoon, Saskatchewan
Male
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy
Official Title  ICMJE A Phase II Neoadjuvant Trial of Sunitinib Malate (SU011248) Plus Hormonal Ablation for Patients Who Have High Risk Localized Prostate Cancer and Will Undergo Prostatectomy
Brief Summary The goal of this clinical research study is to learn if the addition of sunitinib malate (SU011248) to hormone based castration is an effective treatment for shrinking or controlling the tumor before having the prostate removed.
Detailed Description

Sunitinib malate is designed to block pathways that control important events such as the growth of blood vessels that are essential for the growth of cancer. Hormonal treatment is used to lower testosterone levels in the body because prostate cancer cells need testosterone to survive.

Before you can start treatment on this study, you will have what are called "screening tests." These tests will help the doctor decide if you are eligible to take part in this study. Your complete medical history will be recorded. You will have a physical exam, including measurement of vital signs (blood pressure, pulse, temperature, and weight). Blood (about 2 teaspoons) and urine will be collected for routine tests. You will have a computerized tomography (CT) or magnetic resonance imaging (MRI) scan, a bone scan, or a chest x-ray to evaluate the status of your disease. You will be asked about any medications or treatments you are currently taking. You will have an electrocardiogram (ECG - a test that measures the electrical activity of the heart) and an echocardiogram. An echocardiogram uses sound waves to make pictures of your heart, which helps show how well your heart pumps blood. You will be asked to lie on your left side while a technician places a probe with gel on your chest to create images of your heart to determine the function and size. Your ability to perform daily activities will also be evaluated. You will have a bone marrow aspirate and biopsy. To collect a bone marrow aspirate and biopsy, an area of the hip or chest bone is numbed with anesthetic, and a small amount of bone marrow and bone is withdrawn through a large needle.

If you are found to be eligible to take part in this study, you will take the sunitinib malate by mouth 1 time a day for 30 days together with hormonal ablation therapy. You will receive hormone injections to lower the levels of testosterone in the blood. Hormonal therapy may be given either monthly for 3 months or in a single 3-month dose. Every 30 days is considered a study "cycle." You may receive up to 3 cycles of treatment.

On Day 1 of each cycle, you will have a physical exam and you will be asked about your medical history. Blood (about 2 teaspoons) will be drawn for routine tests. You will be asked about any medications you have taken and any side effects you may have experienced. You will be asked questions about your ability to perform daily activities (performance status evaluation.)

On Day 15 of Cycle 1, you will be asked about any side effects you have experienced. Blood (about 2 teaspoons) will be drawn for routine testing.

After completing 3 cycles of treatment, you will have surgery to remove your prostate. The surgery will occur 1-2 weeks after you receive the last dose of study drug.

After the last dose of the study drug, you will have a follow-up visit. You will be asked about any side effects you are experiencing and you will have a physical exam. You will also have digital rectal exam. Blood (about 2 teaspoons) will be drawn for routine tests. You will also have an echocardiogram. An echocardiogram uses sound waves to make pictures of your heart, which helps show how well your heart pumps blood. You will be asked to lie on your left side while a technician places a probe with gel on your chest to create images of your heart to determine the function and size.

You will have a follow-up visit, 28 days after you stop treatment. You will have a physical exam and your complete medical history will be recorded. Blood (about 2 teaspoons) will be drawn for routine tests. You will be asked about any medications you have taken and any side effects you may have experienced. You will have a performance status evaluation. You will have an echocardiogram if it was abnormal at your last visit.

About 3 months after your surgery, you will return for another follow-up visit. You will have a physical exam and your complete medical history will be recorded. Blood (about 2 teaspoons) will be drawn for routine tests. You will have a performance status evaluation.

For the first year after surgery you will have a prostate specific antigen (PSA) blood test every 3 months. Two (2) years after surgery you will begin having PSA tests every 6 months.

This is an investigational study. Sunitinib malate has been authorized by the FDA for research purposes only. About 64 patients will take part in this study. All will be enrolled at M. D. Anderson.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Prostate Cancer
Intervention  ICMJE
  • Drug: LHRH Agonist
    Intramuscular injection either monthly for 3 months or in a single 3-month dose.
    Other Names:
    • Lupron
    • Leuprolide
  • Drug: Sunitinib Malate
    25 to 37.5 mg/day once daily for 30 days (= 1 cycle), up to 3 cycles.
    Other Name: SU011248
  • Procedure: Radical Prostatectomy
    Radical prostatectomy after completion of Sunitinib and LHRH agonist.
Study Arms  ICMJE Experimental: Sunitinib + Hormonal Ablation Before Prostatectomy
Sunitinib Malate 25 to 37.5 mg/day once daily for 30 days (= 1 cycle), up to 3 cycles. LHRH Agonist intramuscular injection either monthly for 3 months or in a single 3-month dose. Radical prostatectomy after completion of Sunitinib and LHRH agonist.
Interventions:
  • Drug: LHRH Agonist
  • Drug: Sunitinib Malate
  • Procedure: Radical Prostatectomy
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Estimated Enrollment  ICMJE
 (submitted: March 9, 2010)
64
Original Enrollment  ICMJE
 (submitted: May 19, 2006)
36
Estimated Study Completion Date  ICMJE December 1, 2021
Estimated Primary Completion Date December 1, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Patients with histologically confirmed adenocarcinoma of the prostate that in the opinion of the surgeon is resectable. Ductal adenocarcinoma of the prostate is included.
  2. All patients must be regarded as low anesthetic risk for radical prostatectomy and confirm their intention to undergo radical prostatectomy at the end of the neoadjuvant therapy.
  3. All patients must have one of the following high-risk features: clinical (c) T(subscript)3 disease or Gleason 8-10 adenocarcinoma or cT(subscript)2(subscript)b-c and PSA >= 10 ng/ml and Gleason 7 adenocarcinoma. The 1992 AJCC staging system will be followed.
  4. ECOG performance status 0 or 1.
  5. Prior hormonal therapy up to 2 months is permitted.
  6. Patients must have adequate bone marrow function defined as an absolute peripheral granulocyte count of >= 1,500/mm^3 and platelet count of >= 100,000/mm^3; hemoglobin >= 9.0g/dl; adequate hepatic function defined as a total bilirubin of <=1.5 mg/dl and AST/ALT <= 2 x the upper limit of normal; adequate renal function defined as serum creatinine <= 1.5 x the upper limits of normal or creatinine clearance >= 40cc/min (measured or calculated).
  7. Patients must sign the current IRB approved informed consent indicating that they are aware of the investigational nature of this study, in keeping with the policies of the institution.
  8. All patients must have a surgical and medical oncology consult prior to signing informed consent.

Exclusion Criteria:

  1. Patients with small cell or sarcomatoid prostate cancers are not eligible.
  2. Patients with clinical or radiological evidence of metastatic disease.
  3. Patients receiving ketoconazole as a prior hormonal therapy.
  4. Prior chemotherapy or experimental agents for prostate cancer.
  5. Patients with any infection process, in the criterion of the investigator, that could worsen or its outcome be affected, as a result of the investigational therapy.
  6. Patients with NYHA Class III/IV congestive heart failure, unstable angina, cerebrovascular accident or transient ischemic attack, or pulmonary embolism or myocardial infarction in the last 6 months.
  7. Uncontrolled severe hypertension (>= 140/90 despite controlling medication), uncontrolled diabetes mellitus, oxygen-dependent lung disease, known chronic liver disease or HIV infection.
  8. Second malignancies (excluding non-melanoma skin cancer) unless disease-free for 3 years.
  9. Ongoing treatment with therapeutic doses of coumadin. However, low dose coumadin up to 2mg PO daily for deep vein thrombosis prophylaxis is allowed. Low molecular weight heparin is allowed.
  10. Overt psychosis, mental disability or otherwise incompetent to give informed consent or history of non-compliance.
Sex/Gender  ICMJE
Sexes Eligible for Study:Male
Ages  ICMJE Child, Adult, Older Adult
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00329043
Other Study ID Numbers  ICMJE 2005-0903
NCI-2012-01364 ( Registry Identifier: NCI CTRP )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party M.D. Anderson Cancer Center
Study Sponsor  ICMJE M.D. Anderson Cancer Center
Collaborators  ICMJE Pfizer
Investigators  ICMJE
Principal Investigator:Amado Zurita, MDM.D. Anderson Cancer Center
PRS Account M.D. Anderson Cancer Center
Verification Date June 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP